Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 89

1.

Ivacaftor in cystic fibrosis with residual function: Lung function results from an N-of-1 study.

Nick JA, St Clair C, Jones MC, Lan L, Higgins M; VX12-770-113 Study Team.

J Cyst Fibros. 2020 Jan;19(1):91-98. doi: 10.1016/j.jcf.2019.09.013. Epub 2019 Nov 26.

2.

Prevention of transmission of Mycobacterium abscessus among patients with cystic fibrosis.

Gross JE, Martiniano SL, Nick JA.

Curr Opin Pulm Med. 2019 Nov;25(6):646-653. doi: 10.1097/MCP.0000000000000621.

PMID:
31436542
3.

Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.

Somayaji R, Russell R, Cogen JD, Goss CH, Nick SE, Saavedra MT, Taylor-Cousar JL, Nick JA, Nichols DP.

Ann Am Thorac Soc. 2019 Jul;16(7):853-860. doi: 10.1513/AnnalsATS.201811-773OC.

PMID:
30840835
4.

Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.

Pohl K, Nichols DP, Taylor-Cousar JL, Saavedra MT, Strand MJ, Nick JA, Bratcher PE.

PLoS One. 2018 Dec 12;13(12):e0209026. doi: 10.1371/journal.pone.0209026. eCollection 2018.

5.

Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis.

Sermet-Gaudelus I, Clancy JP, Nichols DP, Nick JA, De Boeck K, Solomon GM, Mall MA, Bolognese J, Bouisset F, den Hollander W, Paquette-Lamontagne N, Tomkinson N, Henig N, Elborn JS, Rowe SM.

J Cyst Fibros. 2019 Jul;18(4):536-542. doi: 10.1016/j.jcf.2018.10.015. Epub 2018 Nov 19.

6.

Nontuberculous Mycobacterial Infections in Cystic Fibrosis.

Martiniano SL, Nick JA, Daley CL.

Thorac Surg Clin. 2019 Feb;29(1):95-108. doi: 10.1016/j.thorsurg.2018.09.008. Review.

PMID:
30454926
7.

C-terminal proline deletions in KCNC3 cause delayed channel inactivation and an adult-onset progressive SCA13 with spasticity.

Khare S, Galeano K, Zhang Y, Nick JA, Nick HS, Subramony SH, Sampson J, Kaczmarek LK, Waters MF.

Cerebellum. 2018 Oct;17(5):692-697. doi: 10.1007/s12311-018-0950-5.

PMID:
29949095
8.

CFTR modulator theratyping: Current status, gaps and future directions.

Clancy JP, Cotton CU, Donaldson SH, Solomon GM, VanDevanter DR, Boyle MP, Gentzsch M, Nick JA, Illek B, Wallenburg JC, Sorscher EJ, Amaral MD, Beekman JM, Naren AP, Bridges RJ, Thomas PJ, Cutting G, Rowe S, Durmowicz AG, Mense M, Boeck KD, Skach W, Penland C, Joseloff E, Bihler H, Mahoney J, Borowitz D, Tuggle KL.

J Cyst Fibros. 2019 Jan;18(1):22-34. doi: 10.1016/j.jcf.2018.05.004. Epub 2018 Jun 20. Review.

9.

Mycobacterial biomaterials and resources for researchers.

Hazbón MH, Rigouts L, Schito M, Ezewudo M, Kudo T, Itoh T, Ohkuma M, Kiss K, Wu L, Ma J, Hamada M, Strong M, Salfinger M, Daley CL, Nick JA, Lee JS, Rastogi N, Couvin D, Hurtado-Ortiz R, Bizet C, Suresh A, Rodwell T, Albertini A, Lacourciere KA, Deheer-Graham A, Alexander S, Russell JE, Bradford R, Riojas MA.

Pathog Dis. 2018 Jun 1;76(4). doi: 10.1093/femspd/fty042. Review.

10.

Neutrophil killing of Mycobacterium abscessus by intra- and extracellular mechanisms.

Malcolm KC, Caceres SM, Pohl K, Poch KR, Bernut A, Kremer L, Bratton DL, Herrmann JL, Nick JA.

PLoS One. 2018 Apr 19;13(4):e0196120. doi: 10.1371/journal.pone.0196120. eCollection 2018.

11.

Whole Blood Gene Expression Profiling Predicts Severe Morbidity and Mortality in Cystic Fibrosis: A 5-Year Follow-Up Study.

Saavedra MT, Quon BS, Faino A, Caceres SM, Poch KR, Sanders LA, Malcolm KC, Nichols DP, Sagel SD, Taylor-Cousar JL, Leach SM, Strand M, Nick JA.

Ann Am Thorac Soc. 2018 May;15(5):589-598. doi: 10.1513/AnnalsATS.201707-527OC.

PMID:
29425066
12.

Nontuberculous mycobacteria in cystic fibrosis: Updates and the path forward.

Martiniano SL, Davidson RM, Nick JA.

Pediatr Pulmonol. 2017 Nov;52(S48):S29-S36. doi: 10.1002/ppul.23825. Epub 2017 Sep 7. Review.

PMID:
28881094
13.

Alternative pre-mRNA splicing of Toll-like receptor signaling components in peripheral blood mononuclear cells from patients with ARDS.

Blumhagen RZ, Hedin BR, Malcolm KC, Burnham EL, Moss M, Abraham E, Huie TJ, Nick JA, Fingerlin TE, Alper S.

Am J Physiol Lung Cell Mol Physiol. 2017 Nov 1;313(5):L930-L939. doi: 10.1152/ajplung.00247.2017. Epub 2017 Aug 3.

14.

Mycobacterium abscessus Displays Fitness for Fomite Transmission.

Malcolm KC, Caceres SM, Honda JR, Davidson RM, Epperson LE, Strong M, Chan ED, Nick JA.

Appl Environ Microbiol. 2017 Sep 15;83(19). pii: e00562-17. doi: 10.1128/AEM.00562-17. Print 2017 Oct 1.

15.

Safety and Effectiveness of Clofazimine for Primary and Refractory Nontuberculous Mycobacterial Infection.

Martiniano SL, Wagner BD, Levin A, Nick JA, Sagel SD, Daley CL.

Chest. 2017 Oct;152(4):800-809. doi: 10.1016/j.chest.2017.04.175. Epub 2017 May 5.

PMID:
28483608
16.

A KCNC3 mutation causes a neurodevelopmental, non-progressive SCA13 subtype associated with dominant negative effects and aberrant EGFR trafficking.

Khare S, Nick JA, Zhang Y, Galeano K, Butler B, Khoshbouei H, Rayaprolu S, Hathorn T, Ranum LPW, Smithson L, Golde TE, Paucar M, Morse R, Raff M, Simon J, Nordenskjöld M, Wirdefeldt K, Rincon-Limas DE, Lewis J, Kaczmarek LK, Fernandez-Funez P, Nick HS, Waters MF.

PLoS One. 2017 May 3;12(5):e0173565. doi: 10.1371/journal.pone.0173565. eCollection 2017.

17.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.

Sanders DB, Solomon GM, Beckett VV, West NE, Daines CL, Heltshe SL, VanDevanter DR, Spahr JE, Gibson RL, Nick JA, Marshall BC, Flume PA, Goss CH; STOP Study Group.

J Cyst Fibros. 2017 Sep;16(5):592-599. doi: 10.1016/j.jcf.2017.04.005. Epub 2017 Apr 29.

18.

Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.

West NE, Beckett VV, Jain R, Sanders DB, Nick JA, Heltshe SL, Dasenbrook EC, VanDevanter DR, Solomon GM, Goss CH, Flume PA; STOP investigators.

J Cyst Fibros. 2017 Sep;16(5):600-606. doi: 10.1016/j.jcf.2017.04.003. Epub 2017 Apr 29.

19.

Diagnosis of Cystic Fibrosis in Nonscreened Populations.

Sosnay PR, White TB, Farrell PM, Ren CL, Derichs N, Howenstine MS, Nick JA, De Boeck K.

J Pediatr. 2017 Feb;181S:S52-S57.e2. doi: 10.1016/j.jpeds.2016.09.068.

PMID:
28129813
20.

Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.

Nichols DP, Happoldt CL, Bratcher PE, Caceres SM, Chmiel JF, Malcolm KC, Saavedra MT, Saiman L, Taylor-Cousar JL, Nick JA.

J Cyst Fibros. 2017 May;16(3):358-366. doi: 10.1016/j.jcf.2016.12.003. Epub 2016 Dec 24.

21.

Glucose >200 mg/dL during Continuous Glucose Monitoring Identifies Adult Patients at Risk for Development of Cystic Fibrosis Related Diabetes.

Taylor-Cousar JL, Janssen JS, Wilson A, Clair CG, Pickard KM, Jones MC, Brayshaw SJ, Chacon CS, Barboa CM, Sontag MK, Accurso FJ, Nichols DP, Saavedra MT, Nick JA.

J Diabetes Res. 2016;2016:1527932. doi: 10.1155/2016/1527932. Epub 2016 Nov 24.

22.

Attenuated heme oxygenase-1 responses predispose the elderly to pulmonary nontuberculous mycobacterial infections.

Surolia R, Karki S, Wang Z, Kulkarni T, Li FJ, Vohra S, Batra H, Nick JA, Duncan SR, Thannickal VJ, Steyn AJ, Agarwal A, Antony VB.

Am J Physiol Lung Cell Mol Physiol. 2016 Nov 1;311(5):L928-L940. doi: 10.1152/ajplung.00397.2015. Epub 2016 Sep 30.

23.

Extremes of Interferon-Stimulated Gene Expression Associate with Worse Outcomes in the Acute Respiratory Distress Syndrome.

Nick JA, Caceres SM, Kret JE, Poch KR, Strand M, Faino AV, Nichols DP, Saavedra MT, Taylor-Cousar JL, Geraci MW, Burnham EL, Fessler MB, Suratt BT, Abraham E, Moss M, Malcolm KC.

PLoS One. 2016 Sep 8;11(9):e0162490. doi: 10.1371/journal.pone.0162490. eCollection 2016.

24.

Nontuberculous mycobacterial infections in cystic fibrosis: to treat or not to treat?

Nick JA, Pohl K, Martiniano SL.

Curr Opin Pulm Med. 2016 Nov;22(6):629-36. doi: 10.1097/MCP.0000000000000317. Review.

PMID:
27583673
25.

Nontuberculous Mycobacterial Infections in Cystic Fibrosis.

Martiniano SL, Nick JA, Daley CL.

Clin Chest Med. 2016 Mar;37(1):83-96. doi: 10.1016/j.ccm.2015.11.001. Epub 2015 Dec 23. Review.

PMID:
26857770
26.

Diagnosis of Adult Patients with Cystic Fibrosis.

Nick JA, Nichols DP.

Clin Chest Med. 2016 Mar;37(1):47-57. doi: 10.1016/j.ccm.2015.11.006. Epub 2015 Dec 23. Review.

PMID:
26857767
27.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS.

Thorax. 2016 Jan;71(1):88-90. doi: 10.1136/thoraxjnl-2015-207983.

28.

US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann JL, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS; US Cystic Fibrosis Foundation and European Cystic Fibrosis Society.

Thorax. 2016 Jan;71 Suppl 1:i1-22. doi: 10.1136/thoraxjnl-2015-207360.

29.

Drug interactions and treatment burden as survival improves.

Nichols DP, Kuk KN, Nick JA.

Curr Opin Pulm Med. 2015 Nov;21(6):617-25. doi: 10.1097/MCP.0000000000000212. Review.

PMID:
26390336
30.

Nontuberculous mycobacterial infections in cystic fibrosis.

Martiniano SL, Nick JA.

Clin Chest Med. 2015 Mar;36(1):101-15. doi: 10.1016/j.ccm.2014.11.003. Review.

PMID:
25676523
31.

Mycobacterium abscessus morphotype comparison in a murine model.

Caverly LJ, Caceres SM, Fratelli C, Happoldt C, Kidwell KM, Malcolm KC, Nick JA, Nichols DP.

PLoS One. 2015 Feb 12;10(2):e0117657. doi: 10.1371/journal.pone.0117657. eCollection 2015.

32.

Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease.

Taylor-Cousar JL, Wiley C, Felton LA, St Clair C, Jones M, Curran-Everett D, Poch K, Nichols DP, Solomon GM, Saavedra MT, Accurso FJ, Nick JA.

J Cyst Fibros. 2015 Mar;14(2):228-36. doi: 10.1016/j.jcf.2014.10.006. Epub 2014 Nov 13.

33.

Endothelin-1-mediated vasoconstriction alters cerebral gene expression in iron homeostasis and eicosanoid metabolism.

Bickford JS, Ali NF, Nick JA, Al-Yahia M, Beachy DE, Doré S, Nick HS, Waters MF.

Brain Res. 2014 Nov 7;1588:25-36. doi: 10.1016/j.brainres.2014.09.022. Epub 2014 Sep 16.

PMID:
25230250
34.

Comparison of radiographic and clinical characteristics of low-risk and high-risk cystic fibrosis genotypes.

Ferril GR, Nick JA, Getz AE, Barham HP, Saavedra MT, Taylor-Cousar JL, Nichols DP, Curran-Everett D, Kingdom TT, Ramakrishnan VR.

Int Forum Allergy Rhinol. 2014 Nov;4(11):915-20. doi: 10.1002/alr.21412. Epub 2014 Sep 15.

PMID:
25224556
35.

Enhanced in vitro formation and antibiotic resistance of nonattached Pseudomonas aeruginosa aggregates through incorporation of neutrophil products.

Caceres SM, Malcolm KC, Taylor-Cousar JL, Nichols DP, Saavedra MT, Bratton DL, Moskowitz SM, Burns JL, Nick JA.

Antimicrob Agents Chemother. 2014 Nov;58(11):6851-60. doi: 10.1128/AAC.03514-14. Epub 2014 Sep 2.

36.

KCNC3(R420H), a K(+) channel mutation causative in spinocerebellar ataxia 13 displays aberrant intracellular trafficking.

Gallego-Iradi C, Bickford JS, Khare S, Hall A, Nick JA, Salmasinia D, Wawrowsky K, Bannykh S, Huynh DP, Rincon-Limas DE, Pulst SM, Nick HS, Fernandez-Funez P, Waters MF.

Neurobiol Dis. 2014 Nov;71:270-9. doi: 10.1016/j.nbd.2014.08.020. Epub 2014 Aug 22.

37.

Expression of antimicrobial drug tolerance by attached communities of Mycobacterium tuberculosis.

Ackart DF, Hascall-Dove L, Caceres SM, Kirk NM, Podell BK, Melander C, Orme IM, Leid JG, Nick JA, Basaraba RJ.

Pathog Dis. 2014 Apr;70(3):359-69. doi: 10.1111/2049-632X.12144. Epub 2014 Feb 24.

38.

Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.

Nick JA, Moskowitz SM, Chmiel JF, Forssén AV, Kim SH, Saavedra MT, Saiman L, Taylor-Cousar JL, Nichols DP.

Ann Am Thorac Soc. 2014 Mar;11(3):342-50. doi: 10.1513/AnnalsATS.201310-352OC.

39.

Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis.

Martiniano SL, Sontag MK, Daley CL, Nick JA, Sagel SD.

Ann Am Thorac Soc. 2014 Jan;11(1):36-44. doi: 10.1513/AnnalsATS.201309-310OC.

40.

The role of leptin in the development of pulmonary neutrophilia in infection and acute lung injury.

Ubags ND, Vernooy JH, Burg E, Hayes C, Bement J, Dilli E, Zabeau L, Abraham E, Poch KR, Nick JA, Dienz O, Zuñiga J, Wargo MJ, Mizgerd JP, Tavernier J, Rincón M, Poynter ME, Wouters EF, Suratt BT.

Crit Care Med. 2014 Feb;42(2):e143-51. doi: 10.1097/CCM.0000000000000048.

41.

Blood mRNA biomarkers for detection of treatment response in acute pulmonary exacerbations of cystic fibrosis.

Nick JA, Sanders LA, Ickes B, Briones NJ, Caceres SM, Malcolm KC, Brayshaw SJ, Chacon CS, Barboa CM, Jones MC, St Clair C, Taylor-Cousar JL, Nichols DP, Sagel SD, Strand M, Saavedra MT.

Thorax. 2013 Oct;68(10):929-37. doi: 10.1136/thoraxjnl-2012-202278. Epub 2013 Jun 19.

PMID:
23783371
42.

p53 Integrates host defense and cell fate during bacterial pneumonia.

Madenspacher JH, Azzam KM, Gowdy KM, Malcolm KC, Nick JA, Dixon D, Aloor JJ, Draper DW, Guardiola JJ, Shatz M, Menendez D, Lowe J, Lu J, Bushel P, Li L, Merrick BA, Resnick MA, Fessler MB.

J Exp Med. 2013 May 6;210(5):891-904. doi: 10.1084/jem.20121674. Epub 2013 Apr 29.

43.

Selective metabolism of hypothiocyanous acid by mammalian thioredoxin reductase promotes lung innate immunity and antioxidant defense.

Chandler JD, Nichols DP, Nick JA, Hondal RJ, Day BJ.

J Biol Chem. 2013 Jun 21;288(25):18421-8. doi: 10.1074/jbc.M113.468090. Epub 2013 Apr 29.

44.

Effects of azithromycin in Pseudomonas aeruginosa burn wound infection.

Nichols DP, Caceres S, Caverly L, Fratelli C, Kim SH, Malcolm K, Poch KR, Saavedra M, Solomon G, Taylor-Cousar J, Moskowitz S, Nick JA.

J Surg Res. 2013 Aug;183(2):767-76. doi: 10.1016/j.jss.2013.02.003. Epub 2013 Feb 24.

45.

Mycobacterium abscessus induces a limited pattern of neutrophil activation that promotes pathogen survival.

Malcolm KC, Nichols EM, Caceres SM, Kret JE, Martiniano SL, Sagel SD, Chan ED, Caverly L, Solomon GM, Reynolds P, Bratton DL, Taylor-Cousar JL, Nichols DP, Saavedra MT, Nick JA.

PLoS One. 2013;8(2):e57402. doi: 10.1371/journal.pone.0057402. Epub 2013 Feb 25.

46.

Neutrophils regulate tissue Neutrophilia in inflammation via the oxidant-modified lipid lysophosphatidylserine.

Frasch SC, Fernandez-Boyanapalli RF, Berry KA, Murphy RC, Leslie CC, Nick JA, Henson PM, Bratton DL.

J Biol Chem. 2013 Feb 15;288(7):4583-93. doi: 10.1074/jbc.M112.438507. Epub 2013 Jan 5.

47.

Neutrophil extracellular trap (NET)-mediated killing of Pseudomonas aeruginosa: evidence of acquired resistance within the CF airway, independent of CFTR.

Young RL, Malcolm KC, Kret JE, Caceres SM, Poch KR, Nichols DP, Taylor-Cousar JL, Saavedra MT, Randell SH, Vasil ML, Burns JL, Moskowitz SM, Nick JA.

PLoS One. 2011;6(9):e23637. doi: 10.1371/journal.pone.0023637. Epub 2011 Sep 1.

48.

Bacteria-specific neutrophil dysfunction associated with interferon-stimulated gene expression in the acute respiratory distress syndrome.

Malcolm KC, Kret JE, Young RL, Poch KR, Caceres SM, Douglas IS, Coldren CD, Burnham EL, Moss M, Nick JA.

PLoS One. 2011;6(7):e21958. doi: 10.1371/journal.pone.0021958. Epub 2011 Jul 6.

49.

Disruption of contact lens-associated Pseudomonas aeruginosa biofilms formed in the presence of neutrophils.

Robertson DM, Parks QM, Young RL, Kret J, Poch KR, Malcolm KC, Nichols DP, Nichols M, Zhu M, Cavanagh HD, Nick JA.

Invest Ophthalmol Vis Sci. 2011 Apr 27;52(5):2844-50. doi: 10.1167/iovs.10-6469. Print 2011 Apr.

50.

Effects of gender and age at diagnosis on disease progression in long-term survivors of cystic fibrosis.

Nick JA, Chacon CS, Brayshaw SJ, Jones MC, Barboa CM, St Clair CG, Young RL, Nichols DP, Janssen JS, Huitt GA, Iseman MD, Daley CL, Taylor-Cousar JL, Accurso FJ, Saavedra MT, Sontag MK.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):614-26. doi: 10.1164/rccm.201001-0092OC. Epub 2010 May 6.

Supplemental Content

Support Center